

# Revisiting Fetal Acetaminophen Exposure: Mechanistic BioModels, Predictive Risk, and Policy Reform

2025

## Abstract

The recent HHS announcement acknowledging concerns about prenatal acetaminophen (APAP) and neurodevelopmental outcomes demands a shift from debate to constructive frameworks. A 2025 systematic review using Navigation Guide methodology found consistent evidence linking prenatal APAP to neurodevelopmental disorders [Navarro et al., 2025]. Here, we introduce a novel integrative BioModel that synthesizes oxidative stress, endocrine disruption, epigenetic reprogramming, oligodendrocyte injury, frequency-selective myelination disruption, and connectome remodeling into a predictive system. We present comprehensive visual evidence including chromosomal distribution of ASD risk loci, mechanistic pathway diagrams, and frequency-specific transmission models that illustrate the multi-scale effects of APAP exposure. This model has testable hypotheses, suggests new clinical guidelines (co-formulation with folate, MRI monitoring, genetic/epigenetic screening, EEG frequency analysis), and informs policy recommendations (label reform, moderated use guidelines, and long-term surveillance).

## 1 Introduction: Faustian Bargains in Medicine

The recent announcement linking fetal acetaminophen exposure to autism is not the first time this concern has been raised. For more than four decades, I have followed the literature on autism's genetic and environmental underpinnings. The argument that acetaminophen may play a role has circulated since the 1990s, with the number of publications growing year after year. Now, political figures have brought the debate back into public view, casting themselves as crusaders uncovering "Faustian bargains" in medicine.

The metaphor is apt. In healthcare, multiple things can be true at once. Ibuprofen may be the "least bad" analgesic option during pregnancy, and yet it still carries side effects. Acetaminophen has long been considered safe, even appearing in board exam questions as the correct clinical answer. But if fetal exposure does contribute to autism risk, then the profession must reckon with what liability exists when "best practice" itself carried hidden risks.

The story of Faust reminds us that personal interest is not inherently wrong; it becomes tragic only when combined with greed, predation, or a refusal to acknowledge changing circumstances. In this case, the circumstances are clear: what once seemed safe may require

new caution. Forgiveness is possible—we were doing the best we could with the knowledge we had—but forgiveness does not excuse cover-ups or resistance to updating policy. The path forward requires honesty, transparency, and humility.

Yet the dilemma remains. Are women to have no pain medication during pregnancy? The real challenge is not a binary choice between suffering and risk, but rather building a society more supportive of neurodivergent and endocrine-divergent individuals. Autism is not a moral failing but a developmental variation with complex genetic and environmental roots. The responsibility of medicine is not to eliminate difference, but to minimize preventable harm while ensuring dignity and inclusion.

## 2 The Scientific Context

Early hypotheses about the acetaminophen-autism connection emerged from observations of temporal associations with autism prevalence [Schultz et al., 2008, Torres et al., 2003, Shaw et al., 2013], followed by mechanistic proposals [Parker et al., 2020] and epidemiological confirmation [Liew et al., 2016, ?]. For decades, acetaminophen was considered the safest analgesic in pregnancy [Kristensen et al., 2016], yet evidence has accumulated linking prenatal exposure to elevated risk of autism spectrum disorder (ASD) and ADHD [Masarwa et al., 2018, Chen et al., 2023].

This paper presents an integrative BioModel that synthesizes oxidative stress, endocrine disruption, epigenetic reprogramming, oligodendrocyte injury, frequency-selective myelination disruption, and connectome remodeling into a predictive system. Rather than treating these as isolated mechanisms, we propose an integrated cascade where multiple pathways converge on myelination disruption as the critical intermediate phenotype linking acetaminophen exposure to neurodevelopmental outcomes.




Figure 1: Sankey diagram illustrating the flow of myelination disruption from prenatal APAP exposure through multiple biological pathways to neurodevelopmental outcomes. The width of flows represents the relative contribution of each pathway to the overall effect.




Figure 2: Timeline of human fetal brain development showing critical periods of neurogenesis, gliogenesis, and myelination. These developmental windows coincide with periods of heightened vulnerability to pharmacological disruption, including APAP exposure.

## 3 Methods

### 3.1 Gene/Loci Curation

We compiled a comprehensive catalog of 102 ASD-associated genetic loci verified through the 2017 autism genomics consortium standards. Each locus was annotated with chromosomal position, gene symbol, functional class, and known biological role. Crosswalk validation was performed against SFARI Gene database and recent GWAS meta-analyses.

### 3.2 Literature Synthesis Strategy

Systematic review following Navigation Guide methodology [Navarro et al., 2025] encompassed:

- Human cohort studies (n=46 reviewed, including Danish National Birth Cohort [Liew et al., 2016], Norwegian Mother and Child Cohort [Brandlistuen et al., 2013, Ystrom et al., 2017])
- Mechanistic in vitro models [Pérez et al., 2012, Posadas et al., 2019]
- Animal developmental studies [Viberg et al., 2014, Philippot et al., 2022, Blecharz-Klin et al., 2018]
- Placental transcriptomics and biomarker data [Ji et al., 2020]
- Frequency-selective myelination literature from demyelinating disease models

### 3.3 BioModel Development

Systems biology approach using coupled ordinary differential equations (ODEs) to integrate multiple biological scales. Model parameters derived from empirical studies, including oligodendrocyte toxicity data (90% OPC death at 20mM APAP) [Pérez et al., 2012] and testosterone suppression measurements (40% reduction after 7-day exposure) [Kristensen et al., 2016]. Frequency-dependent transmission dynamics incorporated based on myelin resonance properties.

## 4 Results

### 4.1 Genetic Architecture of Autism

Analysis of 102 verified ASD loci revealed distinct functional categories affecting neurodevelopment. Figure 3 presents the chromosomal distribution of these loci, highlighting the concentration on chromosomes X, 2, and 7. Key findings include:




Figure 3: Ideogram showing distribution of 102 ASD-associated genetic loci across human chromosomes. Chromosomes 2, 7, and X (highlighted) show the highest concentration of risk loci. The X chromosome's 25 loci (24.5% of total) may contribute to male predominance in ASD.

- Concentration of risk genes on chromosomes X (25 loci), 2 (13 loci), and 7 (11 loci)

- Major functional categories: synaptic adhesion molecules (15%), transcription factors (18%), chromatin remodelers (8%)
- X-linked genes account for 24.5% of all ASD loci, potentially explaining male predominance
- Critical genes include CHD8, SHANK3, FMR1, and neurexin/neuroligin families

#### 4.1.1 Enrichment of Myelination Genes in ASD Architecture

Of the 102 ASD-associated genetic loci identified, a striking enrichment exists for genes involved in oligodendrocyte biology and myelination. While genes directly regulating myelination represent less than 2% of the human genome, they account for approximately 15-20% of high-confidence ASD risk loci. This 7- to 10-fold enrichment suggests that myelination disruption represents a convergent pathway in autism etiology.

**Direct Oligodendrocyte/Myelin Genes** The following ASD risk genes have documented primary roles in oligodendrocyte function or myelin formation:

- **CNTNAP2** (chr7): Encodes contactin-associated protein-2, essential for node of Ranvier formation and myelin sheath organization. Mutations cause cortical dysplasia and severe white matter abnormalities.
- **PTEN** (chr10): Critical negative regulator of the PI3K/AKT/mTOR pathway in oligodendrocytes. PTEN deletion causes hypermyelination initially, followed by myelin breakdown.
- **TSC1/TSC2** (chr9/16): mTOR pathway regulators controlling oligodendrocyte differentiation timing and myelin thickness. Haploinsufficiency leads to hypomyelination in tuberous sclerosis.
- **CHD7/CHD8** (chr8/14): Chromatin remodelers required for oligodendrocyte specification from neural progenitors. CHD7 mutations cause CHARGE syndrome with white matter defects.
- **MECP2** (chrX): Methyl-CpG binding protein regulating oligodendrocyte maturation and myelin gene expression. Loss-of-function causes delayed myelination in Rett syndrome.
- **TCF4** (chr18): Basic helix-loop-helix transcription factor in the oligodendrocyte differentiation cascade downstream of OLIG2.
- **MEF2C** (chr5): Myocyte enhancer factor controlling the timing of oligodendrocyte differentiation and myelin gene activation.
- **SOX5** (chr12): SRY-box transcription factor that, with SOX6, inhibits premature oligodendrocyte differentiation, ensuring proper myelination timing.

- **FOXP1** (chr14): Forkhead box transcription factor affecting telencephalic oligodendrocyte progenitor specification.
- **PAFAH1B1/LIS1** (chr17): Platelet-activating factor acetylhydrolase required for oligodendrocyte development and white matter tract formation.

**Indirect Myelination Effects** Additional ASD risk genes influence myelination through secondary mechanisms:

- **BDNF** (chr11): Brain-derived neurotrophic factor promoting oligodendrocyte survival and activity-dependent myelination. BDNF-TrkB signaling enhances myelin protein expression.
- **FMR1** (chrX): Fragile X mental retardation protein affecting translation of myelin basic protein (MBP) mRNA. Loss causes white matter microstructural abnormalities.
- **NRXN1** (chr2): Presynaptic cell adhesion molecule influencing activity-dependent myelination. Deletion associated with reduced white matter volume.
- **MET** (chr7): Hepatocyte growth factor receptor affecting oligodendrocyte migration and survival during development.
- **RELN** (chr7): Reelin glycoprotein influencing radial glia that give rise to oligodendrocyte progenitors.
- **UBE3A** (chr15): E3 ubiquitin ligase affecting oligodendrocyte maturation through protein degradation pathways.

**Clinical Implications of Myelination Gene Enrichment** This enrichment has profound implications for understanding ASD pathogenesis and the potential impact of environmental factors like acetaminophen. The convergence of genetic risk on myelination pathways suggests that:

1. Environmental insults affecting oligodendrocytes (such as APAP toxicity) would interact multiplicatively with genetic vulnerability
2. The 4:1 male predominance in ASD may partially reflect sex differences in myelination trajectories, as males show earlier but more vulnerable hypermyelination patterns
3. Therapeutic interventions targeting myelin repair or oligodendrocyte support could benefit a substantial subset of ASD cases

Given that 15-20% of ASD genetic risk converges on myelination, and acetaminophen directly toxic to oligodendrocyte precursor cells at therapeutic concentrations [Pérez et al., 2012], the intersection of genetic and environmental risk at this cellular nexus provides a biologically plausible mechanism for gene-environment interaction in autism etiology.

## 4.2 Mechanistic Model of Action

Emerging evidence suggests that prenatal APAP perturbs multiple biological pathways [Baker et al., 2020, Kristensen et al., 2016, Zhu et al., 2021]. Our model treats these not as siloed mechanisms, but as an integrated cascade.

### 4.2.1 Oxidative Stress and Mitochondrial Dysfunction

APAP metabolite NAPQI depletes glutathione, generating reactive oxygen species (ROS) that damage oligodendrocytes and neurons [Parker et al., 2020, Posadas et al., 2019]. Placental transcriptomics show downregulation of oxidative phosphorylation genes. In rodents, therapeutic-equivalent doses cause hippocampal oxidative stress within hours [Philippot et al., 2022, Riffel et al., 2020].

### 4.2.2 Endocrine Disruption

Human fetal testes cultures exposed to APAP show 40% reduction in testosterone production [Kristensen et al., 2016, van Maldergem et al., 2018]. This anti-androgenic effect occurs at therapeutic concentrations, disrupting masculinization and potentially contributing to sex-specific ASD prevalence. Placental steroidogenesis is similarly affected.

### 4.2.3 Epigenetic Reprogramming

Cord blood from exposed infants shows altered methylation at neurodevelopmental loci [Ji et al., 2020]. APAP disrupts one-carbon metabolism, affecting SAM production and DNA methylation maintenance. These epigenetic changes may mediate gene-environment interactions in ASD susceptibility.

### 4.2.4 Oligodendrocyte Toxicity and Myelination Delay

APAP is directly toxic to oligodendrocyte precursor cells (OPCs), with 20mM exposure causing 90% cell death in culture [Pérez et al., 2012]. Even 1mM reduces oligodendrocyte markers by 25%. Early postnatal exposure in mice reduces BDNF and myelin-related proteins [Blecharz-Klin et al., 2018]. PGE2 suppression by APAP further impairs oligodendrocyte maturation.

As illustrated in Figure 4, this oligodendrocyte toxicity represents a critical convergence point in the mechanistic cascade.

### 4.2.5 Frequency-Selective Myelination Disruption

A novel aspect of our model is the frequency-dependent nature of APAP's effects on neural transmission. Figure 5 demonstrates how normal sex differences in myelination patterns create differential vulnerability. Males typically exhibit narrow, peaked frequency responses due to hypermyelination of specific circuits, while females show broader frequency responses. APAP exposure causes both hypomyelination (reducing peak transmission) and feminization of male circuits (broadening the frequency response).

The myelin-axon system exhibits resonant frequencies dependent on myelin thickness:

$$f_{res}(M) = k_{base} \sqrt{\frac{M}{M_0}} \cdot (1 - \delta_{sex}) \quad (1)$$

where  $M$  represents myelin thickness,  $M_0$  baseline thickness, and  $\delta_{sex}$  accounts for sex-specific differences.

**Evidence from Demyelinating Diseases** Multiple sclerosis provides a natural model for understanding frequency-specific disruptions. MS patients exhibit:

- Increased low-frequency alpha1 (4-8 Hz) and decreased high-frequency alpha2 (8-12 Hz) power
- Beta-band hyperconnectivity correlating with fatigue severity
- Preserved theta but disrupted gamma oscillations

These frequency-specific patterns suggest APAP-induced hypomyelination would selectively impair higher-frequency neural communication while preserving lower-frequency oscillations.

**Sex Differences in Myelination Patterns** Males exhibit greater within-hemispheric connectivity and enhanced modularity, while females show predominant between-hemispheric connectivity. Most brain regions show later peak age of myelination in women compared to men (3.5 years average difference), with sex-specific hemispheric asymmetries in juxtacortical white matter. These architectural differences create differential vulnerability to frequency-selective disruption.

#### 4.2.6 Altered Connectome

Human fMRI studies find weaker frontoparietal connectivity in exposed children [Baker et al., 2020], while rodent models reveal rigid learning and reduced social play [Blecharz-Klin et al., 2018, Viberg et al., 2014]. Cord blood biomarkers of in utero exposure correlate with later ADHD and ASD diagnoses [Ji et al., 2020]. These findings support the hypothesis of ASD as a “connectopathy” with frequency-specific disruptions.

### 4.3 Comprehensive Mechanistic Framework

## 5 Integrative Systems Biology BioModel

### 5.1 Conceptual Foundation

To evaluate whether combined mechanisms can produce ASD-related outcomes, we developed a systems biology BioModel integrating pathways as coupled differential equations. Each equation encodes one facet and its interaction with APAP.

We propose three complementary conceptual models to understand APAP’s impact on developing neural tissue:

Table 1: Proposed Mechanisms Linking Prenatal APAP to ASD with Supporting Evidence and Implications

Mechanism	Supporting Evidence	Neurodevelopmental Implications
Oxidative Stress & Mitochondrial Dysfunction	<p><b>Animal:</b> Prenatal or neonatal APAP in rodents increases markers of reactive oxygen species (ROS) and oxidative damage in the fetal brain, even at therapeutic-equivalent doses.</p> <p><b>Human:</b> Placental gene analyses from exposed pregnancies show downregulation of oxidative phosphorylation (mitochondrial energy) genes, suggesting impaired energy metabolism.</p>	High ROS and depleted antioxidants (e.g. glutathione) can injure developing neurons and oligodendrocytes and disrupt ATP-dependent brain growth. Oxidative stress may also trigger neuroinflammation, compounding injury and affecting circuit formation.
Epigenetic Re-programming & Gene Expression	<p><b>Human Epidemiology:</b> Prenatal APAP use associated with DNA methylation changes in cord blood and placenta at genes important for neurodevelopment.</p> <p><b>In Vitro:</b> Human stem cells exposed to APAP during neural differentiation exhibit altered expression of neurodevelopmental genes and chromatin marks.</p> <p><b>Transcriptomics:</b> RNA sequencing in human placentae from APAP users found sex-specific changes.</p>	Stable epigenetic modifications in fetal tissues can lead to lasting misregulation of gene networks during brain development. APAP-induced epigenetic signatures overlap with those seen in ASD, suggesting a mechanistic bridge from exposure to later ASD-like phenotypes.

**The Sponge Model (histology)** The sponge model (Figure 6) represents neural tissue as a porous matrix where APAP and its metabolites permeate through interconnected pathways. Like water saturating a sponge, toxicity spreads through multiple channels simultaneously—vascular, interstitial, and cellular. This model captures the distributed nature of APAP exposure, where no single pathway fully explains the damage, but rather the cumulative saturation across all systems leads to dysfunction.

**The Bark Model (xylogenesis)** The bark model (Figure ??) draws analogy from tree bark’s resin canals and secretory structures. Just as bark provides protection and transport for trees, oligodendrocytes form protective myelin sheaths while maintaining metabolic support for axons. APAP disrupts these “resin canals” of the nervous system, compromising both the protective (myelin) and nutritive (metabolic support) functions. The radial and axial organization seen in bark microscopy mirrors the highly organized patterns of myelination that develop during critical gestational windows.




Figure 4: Integrated mechanistic pathway from prenatal acetaminophen exposure to ASD risk. The cascade involves multiple convergent mechanisms, with oligodendrocyte toxicity and testosterone disruption as primary drivers of hypomyelination. Critical developmental windows amplify vulnerability.

**The Wire Model (electroencephalography)** The wire model conceptualizes axons as electrical cables where myelin acts as insulation. APAP-induced demyelination creates “shorts” and signal degradation, particularly affecting high-frequency transmissions. This model predicts frequency-selective deficits: preserved low-frequency (theta) but impaired high-frequency (gamma) oscillations, explaining why basic functions remain while complex cognitive integration suffers.

## 5.2 Core Differential Equations

We couple multiple biological processes into a unified framework:




Figure 5: Frequency-dependent transmission efficiency showing sex differences and APAP effects. Normal males show narrow, peaked response (hypermyelinated). APAP exposure causes both hypomyelination (reduced peak) and feminization (broadened response). Note preserved low-frequency transmission despite high-frequency impairment.

$$\frac{dR}{dt} = k_{ROS}(A) - k_{clr}R, \quad (2)$$

$$\frac{dT}{dt} = S_T(t) - k_{A \rightarrow T}AT, \quad (3)$$

$$\frac{dO}{dt} = S_O(t) - k_{tox}(A)O, \quad (4)$$

$$\frac{dE}{dt} = g(R, T) - k_{revert}E, \quad (5)$$

$$\frac{dC}{dt} = h(O, E, T) - k_{mismatch}C. \quad (6)$$

Here  $A$  is fetal APAP burden,  $R$  redox stress,  $T$  androgen level,  $O$  OPC pool,  $E$  an epigenetic state, and  $C$  a connectivity index.

### 5.3 Frequency-Dependent Transmission Dynamics

The frequency-selective properties of myelinated axons introduce an additional layer to our model:

$$T_{eff}(f, M) = T_{max} \cdot \exp\left(-\frac{(f - f_{res})^2}{2\sigma^2}\right) \quad (7)$$

where  $T_{eff}$  represents transmission efficiency at frequency  $f$ . Sex-specific differences emerge through differential myelination patterns:

$$\Delta f_{pass} = \begin{cases} [8 - 20] \text{ Hz}, & \text{male hypermyelinated circuits} \\ [4 - 30] \text{ Hz}, & \text{female balanced circuits} \end{cases} \quad (8)$$




Figure 6: The Sponge Model: Conceptual representation of acetaminophen absorption and distribution across neural tissue. The porous structure illustrates how toxicity permeates through multiple interconnected pathways simultaneously, leading to distributed dysfunction rather than focal damage.

This creates sex-dimorphic vulnerability to APAP-induced frequency filtering deficits, potentially explaining the 4:1 male predominance in ASD.

## 5.4 Critical Windows and Susceptibility

Let  $\tau$  be gestational time. Susceptibility peaks when  $A(\tau)$  overlaps:

- 8–14 weeks (androgen surge;  $\partial T / \partial \tau$  maximal)
- Late gestation (gliogenesis/myelination;  $\partial O / \partial \tau$  maximal)

**Frequency-Specific Critical Periods** Vulnerability to frequency disruption varies by gestational stage:

- **8-14 weeks:** Establishment of oscillatory foundations (theta/alpha)
- **20-28 weeks:** Beta/gamma circuit myelination begins
- **32-40 weeks:** Frequency coupling patterns solidify




Figure 7: Visualization of myelination patterns in neural tissue. The complex branching and wrapping of myelin sheaths around axons illustrates the intricate architecture that can be disrupted by prenatal APAP exposure, leading to frequency-selective transmission deficits.

## 5.5 Model Predictions

- **Dose–duration nonlinearity:** prolonged daily exposure elevates  $R$  and depresses  $T$ ,  $O$  until thresholds induce durable  $E$  changes.
- **Sex-dimorphic sensitivity:** males show larger  $C$  perturbations for a given  $k_{A \rightarrow T}$  due to narrower frequency pass-bands.
- **Frequency-specific deficits:** High-frequency (gamma) communication disproportionately affected while low-frequency (theta) relatively preserved.
- **Mitigation:** reducing  $A$  (indications-only, shortest course) or  $k_{ROS}(A)$  (antioxidant support) curbs risk.

## 6 Causality Appraisal (Bradford Hill Criteria)

### 6.1 Strength of Association


Meta-analyses report OR 1.2-1.5 for ASD/ADHD with prenatal APAP exposure [Masarwa et al., 2018], with stronger associations for prolonged use (OR up to 2.0) [Chen et al., 2023, Liew et al., 2014].

### 6.2 Consistency

Over 30 epidemiological studies across different populations show similar associations [Navarro et al., 2025], including cohorts in Denmark [Liew et al., 2016], Spain [Avella-Garcia et al., 2016], Norway [Brandlistuen et al., 2013], UK [Stergiakouli et al., 2016], and USA [Ji et al., 2020].

### 6.3 Specificity

APAP specifically affects neurodevelopment without comparable effects on other organ systems at therapeutic doses. Other analgesics (ibuprofen, aspirin) show weaker or no associations [Masarwa et al., 2018].



(a) 32 weeks gestational age

(b) Fetal brain MRI showing myelination progression during critical developmental windows. (a) At 22 weeks, early myelination is visible in brain stem and cerebellar regions. (b) At 32 weeks, extensive myelination has occurred throughout white matter tracts. These periods coincide with peak vulnerability to APAP-induced disruption.

## 6.4 Temporality

Exposure precedes outcome; prospective cohorts confirm prenatal APAP use predates neurodevelopmental diagnoses [Liew et al., 2016].

## 6.5 Biological Gradient

Clear dose-response: risk increases with duration and frequency of use [Liew et al., 2014, Chen et al., 2023]. First-trimester exposure alone shows minimal risk; multi-trimester exposure doubles odds.

## 6.6 Plausibility

Multiple biological mechanisms established (oxidative stress, endocrine disruption, oligodendrocyte toxicity, epigenetic changes) with convergence on myelination disruption.

## 6.7 Coherence

Animal models [Viberg et al., 2014, Blecharz-Klin et al., 2018, Philippot et al., 2022] and human biomarker studies [Ji et al., 2020, Baker et al., 2020] align with epidemiological findings.

## 6.8 Experimental Evidence

Ex vivo human fetal tissue shows testosterone suppression [Kristensen et al., 2016]; in vitro OPC cultures demonstrate direct toxicity [Pérez et al., 2012].

## 6.9 Analogy

Other endocrine disruptors (phthalates, BPA) and oxidative stressors show similar neurodevelopmental effects.

# 7 Quantitative Risk Assessment and Policy Applications

## 7.1 Population-Level Impact Modeling

By incorporating population exposure data (e.g., prevalence of APAP use in pregnancy), the model can predict impacts on public health at scale. Given that  $\geq 50\%$  of pregnant women use acetaminophen, even modest individual risk increases could translate to substantial population-level effects. The model could estimate attributable ASD or ADHD cases under various assumptions—valuable information for regulatory agencies.

## 7.2 Testable Predictions and Validation Framework

The model's virtue lies in generating testable predictions for each mechanistic module:

1. **Oxidative Stress:** Predict specific percent drops in antioxidant levels; verify in cord blood or animal models
2. **Hormone Disruption:** Predict testosterone or thyroid hormone reductions; measure in fetal tissues
3. **Oligodendrocyte Maturation:** Predict delays observable via histology or diffusion MRI (as myelination proxy)
4. **Connectivity Alterations:** Predict specific patterns in frontoparietal networks; test via infant neuroimaging
5. **Behavioral Outcomes:** Predict processing speed or social behavior deficits; assess in longitudinal cohorts

## 8 Clinical Guideline Proposals

1. **Risk stratification:** Genetic screening for susceptibility variants (e.g., MTHFR, antioxidant enzyme polymorphisms)
2. **Dosing thresholds:** Limit to  $\geq 2\text{g/day}$ ,  $\geq 3$  consecutive days in pregnancy
3. **Co-formulation:** Universal APAP-folate (5mg) combination products
4. **Biomarker monitoring:** Cord blood NAPQI, placental oxidative markers
5. **Alternative strategies:** Non-pharmacological pain management education
6. **MRI surveillance:** DTI at 6-12 months for exposed infants
7. **EEG screening:** Frequency analysis at 18-24 months to detect early disruptions

## 9 Mechanistically-Informed Intervention Strategies

### 9.1 Targeted Prevention Based on Critical Windows

The model provides leverageable hypotheses for intervention:

- **If oxidative stress is the major driver:** Test antioxidant or mitochondrial support therapies in pregnant animal models to see if neurodevelopmental outcomes improve
- **If hormone disruption is key:** Avoid APAP during the known testosterone surge (end of first trimester in humans)—a nuance that could inform obstetric advice
- **If oligodendrocyte toxicity dominates:** Co-administer neuroprotective agents or schedule APAP use to avoid critical myelination windows

### 9.2 Multi-Scale Integration for Clinical Translation

The model's ability to integrate data across disciplines— toxicology, endocrinology, neuroscience—generates measurable predictions. By providing a framework where small effects on different pathways accumulate, it explains why APAP (a relatively weak toxin or endocrine disruptor by itself) might nonetheless have detectable effects on neurodevelopment when exposure is frequent or prolonged.

## 10 Policy Recommendations

1. **Label reform:** FDA black box warning for pregnancy use
2. **Research funding:** NIH initiative for mechanistic studies and biomarker development
3. **Surveillance:** Establish pregnancy exposure registry with long-term follow-up

4. **Education:** Provider training on risks and alternatives
5. **International coordination:** WHO guidelines for global harmonization

## 11 Discussion

The evidence presented here—from genetic architecture (Figure 3) through mechanistic pathways (Figure 4) to frequency-specific transmission deficits (Figure 5)—supports a coherent model of APAP-induced neurodevelopmental disruption. The microscopic cellular networks affected (Figure ??) provide a tangible visualization of the delicate oligodendrocyte architecture vulnerable to toxic insult.

### 11.1 Clinical Translation

The convergent mechanisms identified suggest multiple intervention opportunities:

1. **Primary Prevention:** Limit APAP use to fever  $>39^{\circ}\text{C}$  or severe pain unresponsive to non-pharmacological measures
2. **Co-formulation Strategy:** Universal APAP-folate combination could buffer oxidative damage
3. **Biomarker Screening:** Cord blood NAPQI metabolites, placental oxidative markers, and fetal testosterone levels
4. **MRI Surveillance:** Diffusion tensor imaging at 6-12 months for exposed infants
5. **Frequency-Based Interventions:** EEG monitoring and targeted neuromodulation for at-risk children

The sex-specific vulnerability patterns revealed by our frequency analysis (Figure 5) suggest that males with narrow frequency pass-bands may benefit from different intervention strategies than females. This could explain why current behavioral interventions show variable efficacy across sexes.

### 11.2 Patient Advocacy and Communication

Plain language summary for patients: “New research suggests acetaminophen during pregnancy may affect baby’s brain development. While still considered safer than other pain medicines, use only when necessary. Talk to your provider about alternatives.”

### 11.3 Implications of Frequency-Selective Disruption

Rather than uniform signal degradation, hypomyelination creates frequency-specific communication deficits:

- 1. Preserved low-frequency functions:** Basic sensory processing and motor control remain relatively intact
- 2. Impaired high-frequency binding:** Deficits in attention, executive function, and social cognition—hallmarks of ASD
- 3. Sex-specific manifestations:** Males' narrower frequency pass-bands create greater vulnerability

This framework suggests novel therapeutic approaches targeting specific oscillatory bands through neuromodulation or pharmacological enhancement of myelination in affected frequency ranges.

## 11.4 Research Roadmap

Priority areas for future investigation:

1. Biomarker development for early detection [Ji et al., 2020]
2. MRI protocols for infant myelination assessment [Baker et al., 2020]
3. Genetic susceptibility markers [Leppert et al., 2019, Schultz et al., 2008]
4. Intervention trials with antioxidant co-administration [Parker et al., 2020]
5. Long-term follow-up of exposed cohorts into adolescence [Liew et al., 2021]
6. EEG-based screening for frequency-specific disruptions
7. Development of frequency-targeted therapeutic interventions

## 11.5 Systems-Level Convergence and Emergent Properties

The model addresses a common critique that “acetaminophen is safe because it’s not a potent teratogen” by demonstrating that multi-pathway convergence of subtle perturbations can yield significant outcomes—an insight aligned with systems biology thinking.

Key emergent properties include:

- **Nonlinear amplification:** Small perturbations across multiple systems can combine supralinearly
- **Critical period sensitivity:** Timing determines whether effects are reversible or permanent
- **Sex-specific vulnerability:** Male-specific testosterone disruption creates differential risk profiles
- **Gene-environment interaction:** Genetic susceptibility factors modulate APAP’s impact

## 11.6 Limitations and Uncertainties

Observational human data face confounding by indication [Liew et al., 2016]; some in vitro doses exceed fetal levels [Pérez et al., 2012]; timing/dose quantification remains imprecise. However, sibling-controlled studies that account for familial confounding still find associations [Brandlistuen et al., 2013, Stergiakouli et al., 2016]. The BioModel is qualitatively calibrated; prospective validation against new cohorts and interventional animal work is required.

## 11.7 Critical Evaluation of Model Uncertainties

### 11.7.1 Causation versus Confounding

All human data are observational; thus we cannot conclusively prove APAP causes ASD. Confounding factors remain a key concern. The underlying reasons for APAP use (maternal infections, fever, pain, inflammation) themselves can affect fetal development. While some large studies controlled for infections, illnesses, and genetics and still found significant associations, fully disentangling APAP’s impact from, say, the effects of high fever (which also elevates ASD risk) remains challenging.

The mechanistic model currently does not incorporate maternal illness or genetic susceptibility—it implicitly attributes risk to APAP alone. In reality, APAP might contribute only a portion of the risk, interacting with other variables (e.g., it could be more harmful in the context of poor maternal antioxidant status or certain genotypes). Future model iterations should integrate such factors by adding fever as a parallel input or a “vulnerability factor” for genetically at-risk fetuses.

### 11.7.2 Dose-Response Relationships at Human-Relevant Levels

A notable gap is understanding the dose-response relationship at human-relevant exposure levels. Some mechanistic findings come from high doses or concentrations:

- Near-complete OPC cell kill occurred at 20 mM APAP in vitro—far above typical fetal blood levels (micromolar range)
- While toxicity was observed at 1 mM in vitro, this is still higher than most fetal exposures from normal dosing
- Real-world pharmacokinetic modeling is needed to translate maternal dosing into fetal brain APAP and metabolite concentrations

Encouragingly, epidemiological studies suggest a dose-duration effect—longer APAP use during pregnancy is linked to greater developmental risk, implying a dose-dependent causal relationship. However, quantifying safe versus risky doses remains an open question.

## 12 Conclusion: Reform, Not Prosecution

Healthcare is built on Faustian bargains. Asbestos prevented fires—until it caused lung cancer. Pesticides increased crop yields—until they disrupted endocrine systems in children. mRNA vaccines addressed COVID in the moment—while leaving us to grapple with long COVID. Cancer treatments save loved ones—while reshaping entire housing markets through demographic change. Each advance carries unintended consequences, and the moral accounting is never as simple as “good” or “bad.”

Acetaminophen belongs on this list. It is not the cause of autism, but it may be a cause—an override of developmental programming in a subset of pregnancies. Autism’s architecture is 80% genetic and 20% epigenetic/environmental, and acetaminophen exposure interacts with both layers. The fact that acetaminophen does not cause Asperger’s in isolation does not absolve it from contributing to autism spectrum phenotypes in the presence of certain genetic and epigenetic profiles.

Our integrative BioModel, supported by comprehensive visualization of the mechanistic cascade (Figures 4-5), translates fragmented evidence into testable, predictive hypotheses. The chromosomal architecture of ASD risk (Figure 3) intersects with APAP-induced disruptions at multiple levels—from molecular oxidative stress to systems-level connectivity alterations. The frequency-selective myelination disruption mechanism provides a unifying framework explaining selective cognitive deficits, sex differences, and potential therapeutic targets.

The consensus of international experts [Bauer et al., 2021] and systematic review evidence [Navarro et al., 2025, Masarwa et al., 2018] support precautionary action. Yet the way forward is not prosecution but reform. We must update protocols, add folate to acetaminophen order sets, and push compounding pharmacies and manufacturers to provide folate-acetaminophen formulations. Pediatric MRI diagnostics should be available to track myelination trajectories. Insurance should cover genetic screening for autism risk. Fetal acetaminophen exposure should be understood as part of a broader category of intersex and endocrine-divergent conditions, alongside PCOS and related syndromes. Schools must offer real options for children on the autism spectrum.

Acknowledging these bargains does not mean despairing. It means refusing to cover up inconvenient truths, adapting our practices, and supporting affected families with both science and compassion. In medicine, unintended consequences are not the end of the world—they are reminders that humility, accountability, and forgiveness must guide us forward.

## A Technical Appendix: Detailed Mathematical Framework

### A.1 Pharmacokinetic Pathway

Acetaminophen (APAP) rapidly crosses the placental barrier, reaching near-equilibrium between maternal and fetal plasma within one hour of ingestion. The fetal concentration  $A_{fetal}$  is modeled as:

$$A_{fetal}(t+1) = A_{maternal}(t) \cdot k_{placental} \cdot (1 - k_{fetal-clear}), \quad (9)$$

$$k_{placental} \approx 0.95, \quad (10)$$

where  $k_{placental}$  denotes the near-immediate transfer rate and  $k_{fetal-clear}$  accounts for fetal clearance.

## A.2 Metabolic Toxicity Pathway

APAP is metabolized by CYP2E1, generating toxic metabolites that induce oxidative stress:

$$CYP2E1_{act}(t) = CYP2E1_{base} \cdot d(t), \quad (11)$$

$$M_{toxic}(t+1) = A_{fetal}(t) \cdot CYP2E1_{act}(t), \quad (12)$$

$$S(t+1) = S(t) + \eta \cdot M_{toxic}(t), \quad (13)$$

where  $d(t)$  encodes developmental stage and  $S(t)$  is cumulative oxidative stress.

## A.3 Endocrine Disruption Pathway

APAP perturbs hormone-dependent processes including testosterone and placental steroidogenesis:

$$T_{eff}(t) = T(t) \cdot (1 - \alpha_{endo} A(t)), \quad (14)$$

$$P_{steroid}(t+1) = P_0 \cdot (1 - \alpha_{steroid} A(t)). \quad (15)$$

Sex-specific sensitivity is introduced:

$$\delta_{sex} = \begin{cases} 0.8, & \text{male fetus,} \\ 0.4, & \text{female fetus.} \end{cases}$$

## A.4 Epigenetic Mechanisms

APAP exposure alters DNA methylation at neurodevelopmental loci:

$$M_i(t+1) = M_i^0 + \alpha_{epi} \cdot A(t) \cdot \sigma_i, \quad (16)$$

where  $M_i(t)$  is the methylation state of gene  $i$ , and  $\sigma_i$  denotes gene-specific sensitivity.

## A.5 Myelination Mechanisms

APAP interferes with oligodendrocyte proliferation and myelin protein expression:

$$OPC(t+1) = OPC(t) \cdot [1 + \beta_{folate} F(t)] \cdot [1 - \beta_{ox} S(t)] \cdot [1 - \beta_{epi} M_{MBP}(t)], \quad (17)$$

$$MBP(t+1) = M_0 \cdot [1 - \gamma_{meth} M_{MBP}(t)] \cdot [1 - \gamma_{ox} S(t)], \quad (18)$$

$$M(t+1) = M(t) + k_m \cdot OL(t) \cdot MBP(t) \cdot \left(1 - \frac{A(t)}{A_{tox}}\right). \quad (19)$$

## A.6 Frequency-Dependent Transmission

The frequency response of myelinated axons is modeled as:

$$H(f, M) = \frac{1}{1 + j2\pi f \tau(M)}, \quad (20)$$

$$\tau(M) = \tau_0 \cdot \left(\frac{M_0}{M}\right)^{1.5}, \quad (21)$$

$$BW_{-3dB} = \frac{1}{2\pi\tau(M)}, \quad (22)$$

where  $H(f, M)$  is the frequency response,  $\tau(M)$  the time constant dependent on myelination, and  $BW_{-3dB}$  the bandwidth.

## A.7 Critical Period Sensitivity

Vulnerability varies across developmental windows:

$$V_{crit} = \begin{cases} 2.0 & \text{first trimester,} \\ 3.5 & \text{second trimester,} \\ 3.0 & \text{third trimester,} \\ 1.5 & \text{early postnatal.} \end{cases}$$

## A.8 Dose-Response Dynamics

Duration and cumulative exposure determine nonlinear amplification:

$$E_{cum}(t+1) = E_{cum}(t) + A(t)\Delta t, \quad (23)$$

$$D(t) = \sigma(E_{cum}(t) - \theta_{chronic}), \quad (24)$$

$$\Phi_{all} \mapsto \Phi_{all} \cdot (1 + \lambda D(t)), \quad (25)$$

where  $\sigma(\cdot)$  is a sigmoid function.

## A.9 Folate Interaction Pathway

Folate buffering is impaired by APAP:

$$F(t+1) = F(t) + S_F(t) - C_F(t) - \alpha_{AFA}(t), \quad (26)$$

$$\Psi_M \mapsto \Psi_M \cdot \max \left( 1, \frac{F^* - F(t)}{F^*} \cdot 2.0 \right). \quad (27)$$

## A.10 Connectome Remodeling

Connectivity depends on hormonal and APAP disruption:

$$\begin{cases} \text{If } T_{eff}(t) > \theta_T : & C_{intra} = 1.8, C_{inter} = 0.6, \\ \text{If } A(t) > \theta_A : & C_{pattern} = \text{intermediate-hyper/hypo myelination}. \end{cases}$$

## A.11 Integrated Pathway Model

The full system is represented as a state update:

$$\mathbf{X}(t) = [OPC(t), OL(t), M(t), A(t), F(t), S(t), T_{eff}(t), M_{epi}(t), C(t)]^T, \quad (28)$$

$$\mathbf{X}(t+1) = f(\mathbf{X}(t), V_{crit}(t), G, M_{mat}(t)), \quad (29)$$

where  $G$  encodes genetic susceptibility and  $M_{mat}(t)$  represents maternal factors.

## A.12 Enhanced Mathematical Framework with Confounding Variables

To address model limitations, we propose an extended framework incorporating maternal illness and genetic susceptibility:

$$\frac{dR}{dt} = k_{ROS}(A) \cdot fillness(I) - k_{clr}R \quad (30)$$

$$\frac{dT}{dt} = S_T(t) - k_{A \rightarrow T}AT - k_{fever}F(t) \quad (31)$$

$$\frac{dO}{dt} = S_O(t) - k_{tox}(A)O \cdot g_{genetic}(G) \quad (32)$$

$$\frac{dE}{dt} = h(R, T, G) - k_{revert}E \quad (33)$$

$$\frac{dC}{dt} = j(O, E, T, V_{crit}) - k_{mismatch}C \quad (34)$$

where  $I$  represents maternal illness state,  $F(t)$  denotes fever episodes,  $G$  encodes genetic vulnerability factors, and  $g_{genetic}(G)$  modulates susceptibility to oligodendrocyte toxicity based on genetic background.

## B Notation

Symbol	Meaning
$A$	Fetal acetaminophen burden
$R$	Redox stress (ROS proxy)
$T$	Fetal androgen level
$O$	OPC pool size
$E$	Epigenetic state (e.g., methylation score)
$C$	Connectivity index
$M$	Myelination level
$f$	Oscillation frequency
$f_{res}$	Resonant frequency
$T_{eff}$	Transmission efficiency
$\delta_{sex}$	Sex-specific modifier

## C ASD-Associated Genetic Loci

### C.1 Overview

This appendix presents the comprehensive crosswalk of 102 autism spectrum disorder (ASD) associated genetic loci verified through 2017 consortium standards. These loci represent high-confidence ASD risk genes with robust statistical support from multiple studies.

### C.2 Chromosomal Distribution

## D Supporting Evidence from Neuroimaging Studies

## References

- Avella-Garcia, C.B., Julvez, J., Fortuny, J., Rebordosa, C., García-Estebar, R., Riaño Galán, I., Tardón, A., et al. (2016). Acetaminophen use in pregnancy and neurodevelopment: Attention function and autism spectrum symptoms. *International Journal of Epidemiology*, 45(6), 1987–1996.
- Baker, B.H., Lugo-Candelas, H., Wu, H., Laue, J.L., Boivin, A., Gillet, O., Aw, C., et al. (2020). Association of prenatal acetaminophen exposure measured in meconium with risk of attention-deficit/hyperactivity disorder mediated by frontoparietal network brain connectivity. *JAMA Pediatrics*, 174(11), 1073–1081.
- Bauer, A.Z., Swan, S.H., Kriebel, D., Liew, Z., Taylor, H.S., Bornehag, C.G., Andrade, A.M., et al. (2021). Paracetamol use during pregnancy—A call for precautionary action. *Nature Reviews Endocrinology*, 17(12), 757–766.

Table 2: Distribution of 102 ASD-associated loci across human chromosomes

Chromosome	Count	Notable Genes
chr1	3	NEGR1, NTNG1, ZNHIT6
chr2	13	NRXN1, DPP10, CNTNAP5, SCN1A, SCN2A
chr3	2	FOXP1, SLC9A9
chr4	1	GABRG1
chr5	3	NIPBL, MEF2C, NSD1
chr6	1	PDE10A
chr7	11	AUTS2, CNTNAP2, FOXP2, MET, RELN
chr8	3	DLGAP2, CHD7, VPS13B
chr9	5	EHMT1, TSC1, LAMC3
chr10	1	PTEN
chr11	4	BDNF, SHANK2, KIRREL3
chr12	5	CACNA1C, GRIN2B, SOX5, AVPR1A
chr13	1	PCDH9
chr14	2	CHD8, FOXG1
chr15	3	SNRPN, UBE3A, GABRB3
chr16	5	TSC2, CREBBP, RBFOX1, KCTD13, ANKRD11
chr17	4	SMG6, PAFAH1B1, RAI1, SLC6A4
chr18	3	C18orf1, KATNAL2, TCF4
chr19	2	ZNF507, PNKP
chr22	1	SHANK3
chrX	25	FMR1, NLGN3, NLGN4X, MECP2, others

Bittker, S.S., Bell, K.R. (2018). Acetaminophen, antibiotics, ear infection, breastfeeding, vitamin D drops, and autism: An epidemiological study. *Neuropsychiatric Disease and Treatment*, 14, 1399–414.

Blecharz-Klin, K., Joniec-Maciejak, I., Piechal, A., Pyrzanowska, J., Widy-Tyszkiewicz, E., Mirowska-Guzel, D. (2018). Early paracetamol exposure decreases brain-derived neurotrophic factor (BDNF) in striatum and affects social behaviour and exploration in rats. *Pharmacology Biochemistry and Behavior*, 168, 25–32.

Brandlistuen, R.E., Ystrom, E., Nulman, I., Koren, G., Nordeng, H. (2013). Prenatal paracetamol exposure and child neurodevelopment: A sibling-controlled cohort study. *International Journal of Epidemiology*, 42(6), 1702–1713.

Chen, L., Hu, Y., Wang, S., Cao, K., Mai, W., Sha, W., Ma, H., et al. (2023). Association of maternal use of analgesics during pregnancy with risk of autism spectrum disorder and attention deficit hyperactivity disorder in children: A systematic review and meta-analysis. *Frontiers in Pediatrics*, 11, 1124982.

Chen, X., Zhang, Y., et al. (2022). Clinical Applications of Fetal MRI in the Brain. *Diagnostics*, 12(3), 764. <https://doi.org/10.3390/diagnostics12030764>

Grosu, G.F., Hopp, A.V., Moca, V.V., et al. (2023). The fractal brain: scale-invariance in structure and dynamics. *Cerebral Cortex*, 33(8), 4574–4605. <https://doi.org/10.1093/cercor/bhac363>

Im, K., Pienaar, R., Paldino, M.J., et al. (2019). Fractal dimension in human cortical surface: Multiple regression analysis with cortical thickness, sulcal depth, and folding area. *Human Brain Mapping*, 40(18), 5231–5243.

Ji, Y., Rilley, A.W., Lee, L.C., Hong, X., Wang, G., Tsai, H.J., Mueller, N.T., et al. (2020). Maternal biomarkers of acetaminophen use and offspring attention deficit hyperactivity disorder. *Brain Sciences*, 10(9), 504.

Kristensen, D.M., Hass, U., Lesn  , L., Lottrup, G., Jacobsen, P.R., Desdoits-Lethimonier, C., Boberg, J., et al. (2016). Intrauterine exposure to mild analgesics is a risk factor for development of male reproductive disorders in human and rat. *Human Reproduction*, 31(1), 235–244.

Krubitzer, L.A., Prescott, T.J. (2024). Neuro-evolutionary evidence for a universal fractal primate brain shape. *eLife*, 13, e92080. <https://doi.org/10.7554/eLife.92080>

Leppert, B., Strunz, S., Seiwert, B., Schlittenbauer, L., Schlichting, R., Pfeiffer, C., R  der, S., et al. (2019). Association of maternal neurodevelopmental risk alleles with early-life exposures. *JAMA Psychiatry*, 76(8), 834–842.

Liew, Z., Ritz, B., Rebordosa, C., Lee, P.C., Olsen, J. (2014). Acetaminophen use during pregnancy, behavioral problems, and hyperkinetic disorders. *JAMA Pediatrics*, 168(4), 313–320.

Liew, Z., Ritz, B., Virk, J., Olsen, J. (2016). Maternal use of acetaminophen during pregnancy and risk of autism spectrum disorders in childhood: A Danish national birth cohort study. *Autism Research*, 9(9), 951–958.

Liew, Z., Ernst, A., Str  m, M., Olsen, J. (2021). Prenatal exposure to acetaminophen and overweight in childhood. *Obesity*, 29(9), 1528–1537.

Masarwa, R., Levine, H., Gorelik, E., Reif, S., Perlman, A., Matok, I. (2018). Prenatal exposure to acetaminophen and risk for attention deficit hyperactivity disorder and autistic spectrum disorder: A systematic review, meta-analysis, and meta-regression analysis of cohort studies. *American Journal of Epidemiology*, 187(8), 1817–1827.

Marzi, C., Giannelli, M., Tessa, C., et al. (2020). Toward a more reliable characterization of fractal properties of the cerebral cortex of healthy subjects during the lifespan. *Scientific Reports*, 10, 16957. <https://doi.org/10.1038/s41598-020-73961-w>

Navarro, C.P., Parzen, M., Rauh, V., Factor-Litvak, P., Herbstman, J.B., et al. (2025). Is exposure to paracetamol during pregnancy associated with risk of neurodevelopmental disorders in childhood and adolescence? A systematic review using the Navigation Guide systematic review methodology. *Paediatric and Perinatal Epidemiology*, In Press.

- Pajevic, S., Basser, P.J., Fields, R.D. (2014). Role of myelin plasticity in oscillations and synchrony of neuronal activity. *Neuroscience*, 276, 135–147.
- Parker, W., Hornik, C.D., Bilbo, S., Holzknecht, Z.E., Gentry, L., Rao, R., Lin, S.S., et al. (2020). The role of oxidative stress, inflammation and acetaminophen exposure from birth to early childhood in the induction of autism. *Journal of International Medical Research*, 45(2), 407–438.
- Pérez, E.R., Pautassi, R.M., Spear, N.E. (2012). Effects of prenatal exposure to ethanol and acetaminophen on oligodendrocyte development. *FASEB Journal*, 26(1 Suppl), 624.9.
- Philippot, G., Hosseini, K., Yakimova, R., Francois, A., Skarballiene, J., Börjesson, S.I. (2022). Prenatal exposure to paracetamol leads to atypical spatial navigation and reduced adaptive flexibility in adulthood in mice. *Science Advances*, 8(39), eabn3782.
- Prayer, D., Kasprian, G., et al. (2023). Fetal MRI: what's new? A short review. *European Radiology Experimental*, 7, 41. <https://doi.org/10.1186/s41747-023-00358-5>
- Posadas, I., Santos, P., Blanco, A., Muñoz-Fernández, M., Ceña, V. (2019). Acetaminophen induces apoptosis in rat cortical neurons. *PLoS One*, 5(12), e15360.
- Riffel, A.P.K., Souza, J.A., Santos, M.C.Q., Horst, A., Scheid, T., Kolberg, C., Belló-Klein, A., et al. (2020). Systemic administration of vitamins C and E attenuates nociception induced by chronic constriction injury of the sciatic nerve in rats. *Brain Research Bulletin*, 160, 116–123.
- Schultz, S.T., Klonoff-Cohen, H.S., Wingard, D.L., Akshoomoff, N.A., Macera, C.A., Ji, M. (2008). Acetaminophen (paracetamol) use, measles-mumps-rubella vaccination, and autistic disorder: The results of a parent survey. *Autism*, 12(3), 293–307.
- Shaw, W. (2013). Evidence that increased acetaminophen use in genetically vulnerable children appears to be a major cause of the epidemics of autism, attention deficit with hyperactivity, and asthma. *Journal of Restorative Medicine*, 2(1), 14–29.
- Stergiakouli, E., Thapar, A., Davey Smith, G. (2016). Association of acetaminophen use during pregnancy with behavioral problems in childhood: Evidence against confounding. *JAMA Pediatrics*, 170(10), 964–970.
- Torres, A.R. (2003). Is fever suppression involved in the etiology of autism and neurodevelopmental disorders? *BMC Pediatrics*, 3, 9.
- van Maldergem, L., Hass, U., Touraine, R., Lesné, L., et al. (2018). Combined in vitro/in vivo approach to identify potential endocrine disruptors. *Reproductive Toxicology*, 75, 56–64.
- Viberg, H., Eriksson, P., Gordh, T., Fredriksson, A. (2014). Paracetamol (acetaminophen) administration during neonatal brain development affects cognitive function and alters its analgesic and anxiolytic response in adult male mice. *Toxicological Sciences*, 138(1), 139–147.

Ystrom, E., Gustavson, K., Brandlistuen, R.E., Knudsen, G.P., Magnus, P., Susser, E., Davey Smith, G., et al. (2017). Prenatal exposure to acetaminophen and risk of ADHD. *Pediatrics*, 140(5), e20163840.

Zhu, J.L., Vestergaard, M., Hjollund, N.H., Olsen, J. (2021). Prenatal exposure to acetaminophen and childhood neurodevelopmental disorders. *European Journal of Epidemiology*, 36(9), 993–1004.




Figure 9: Evidence from neuroimaging and histological studies showing myelination disruption patterns in neurodevelopmental disorders. These findings support the proposed mechanism of APAP-induced oligodendrocyte injury and subsequent connectivity alterations.